



Syngene

Putting Science to Work



The background of the entire page is a dark blue server room. In the foreground, a woman in a light blue shirt and dark skirt stands looking at a laptop. She is surrounded by glowing blue and purple lines that represent data connections, flowing through the server racks. In the background, a globe is visible, overlaid with a network of white lines connecting various points, symbolizing global data connectivity.

SynSight: Syngene's data consortium

A voluntary participation
initiative to enable
improved predictive
insights and better, faster
outcomes in drug discovery



SynSight is an opt-in consortium of clients who consent to anonymized usage of their data towards predictive models with higher reliability and broader applicability, leading to better decision-making, timelines, and outcomes on their projects.

It provides a common platform for members to benefit from the learnings on larger volume, standardized data while protecting proprietary information.

Benefits of SynSight

Predictive models are integral to modern drug discovery. They help in molecule design and prioritization, increase efficiency, and inform decision-making throughout the drug discovery process. The accuracy of these models is sensitive to the quality and coverage of the data used to train them. Access to standardized, broad data is the biggest challenge in developing reliable models and applications of artificial intelligence in drug discovery.

We envision SynSight to facilitate quality predictive insights that enable informed decisions for its participating members. Being part of the consortium allows access to learnings from broader data that have better accuracy and applicability. Members can leverage these insights to improve the speed and quality of their projects, leading to shorter design-make-test-analyze (DMTA) cycle times and better outcomes.




Figure 1: SynSight enables access to better predictive models across member projects

Data used

While projects at Syngene generate diverse data, only specific data types that do not compromise proprietary information are used for consortium activities (Figure 2). Project-sensitive data, such as biological activity, is not part of the purview of the consortium.

A consortium member is not required to participate under all the categories. For example, a member may opt to join SynSight for only biologics. Access to models will then be restricted to the category they participate in.




Figure 2: Data types used in SynSight

Ensuring data confidentiality

SynSight ensures data confidentiality by applying solutions such as data anonymization and federated learning. Anonymization embeds molecular data into fingerprints or features, which are used to train the models. The solution makes reconstruction of the parent data practically impossible.




Figure 3: Anonymized learning in SynSight

As evident from Figures 1 and 3, the parent data of the members is not aggregated. Only anonymized data is aggregated to train the models. The models, thus, do not retain any molecular information from the parent data.

Where possible, federated learning is used to add an additional layer of data confidentiality.




Figure 4: Federated learning in SynSight

Syngene has internationally recognized information security management systems (ISO 27001:2013 certified) in place, along with best practices for IT and cybersecurity to protect against cyber attacks and scrutiny. These systems and practices are designed to prevent data leaks and always maintain data integrity and confidentiality.



Frequently asked questions

Is there a minimum participation period?

SynSight requires a minimum participation period of one year.

Is it possible to exit the consortium?

Membership to the consortium can be discontinued by giving a three-month notice before the intended exit date.

What happens to the data and models if a member exits the consortium?

The exiting member can no longer access the models after the exit date. SynSight will subsequently discontinue usage of the customer's data. However, there shall be no retrospective effect – SynSight will not be able to retrieve and destroy any models built on training sets that included the exiting member's data before notice of termination.

Who does the data belong to?

The source data is the property of the contributing member. SynSight anonymizes this data before model creation to ensure that raw data is not directly consumed. No data, raw or anonymized, is made available as part of the consortium.

Will Syngene monetize the data?

SynSight is a not-for-profit initiative to improve drug discovery outcomes for participating clients. Syngene will not monetize any of the models by licensing them for external use.

To know more about SynSight, [contact our experts](#) 





About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's 5000+ scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb, as well as 2.2 million sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis, and Merck KGaA.

For more details, visit www.syngeneintl.com or write to us at bdc@syngeneintl.com

© 2025 Syngene International Limited, All Rights Reserved.

Stay Connected